Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Till Sprenger

University Hospital of Zurich

Switzerland

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Professors in Switzerland Professors in Neuropsychology Neuropsychology professors in Switzerland

Articles (10)

Year:

2025

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (2)

Douglas Arnold

Distinguished James McGill Professor

McGill University

CANADA

View details

Amit Bar-Or

Professor

University of Pennsylvania

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Till Sprenger

Research Interests

Make your next move.

Explore related searches

Articles (10)

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS

Classification of multiple sclerosis based on patterns of CNS regional atrophy covariance

Ponesimod Compared with Teriflunomide in Patients with Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial

Regional Cerebellar Volume Loss Predicts Future Disability in Multiple Sclerosis Patients

Efficacy of inpatient personalized multidisciplinary rehabilitation in multiple sclerosis: behavioural and functional imaging results.

Structural and functional footprint of visual snow syndrome.

Longitudinal patterns of cortical thinning in multiple sclerosis.

Volume loss in the deep gray matter and thalamic subnuclei: a longitudinal study on disability progression in multiple sclerosis.

White matter lesion location correlates with disability in relapsing multiple sclerosis.

Long-term safety and efficacy of daclizumab beta in relapsing–remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study

Collaborators (2)

Douglas Arnold

Amit Bar-Or

Make your next move.